Enhancing Clinical Diagnosis for Patients With Persistent Pulmonary Abnormalities After COVID-19 Infection: The Potential Benefit of 68 Ga-FAPI PET/CT.
Clin Nucl Med
; 47(12): 1026-1029, 2022 Dec 01.
Article
in English
| MEDLINE | ID: covidwho-2078007
ABSTRACT
PATIENTS AND METHODS:
Six post COVID-19 patients suspected for pulmonary fibrosis were scheduled for dual-tracer PET/CT with 18 F-FDG and 68 Ga-fibroblast activation protein inhibitor (FAPI)-46. The uptake of 68 Ga-FAPI-46 in the involved lung was compared with a control group of 9 non-COVID-19 patients. Clinical data and PET/CT imaging were collected and analyzed.RESULTS:
PET/CT revealed in all 6 pulmonary impaired patients the reduced glucose avidity on 18 F-FDG and clear positivity on 68 Ga-FAPI-46 PET/CT in comparison to the control group.CONCLUSIONS:
Enhancing fibrotic repair mechanisms, 68 Ga-FAPI PET/CT may improve noninvasive clinical diagnostic performance in patients with long-term CT abnormalities after severe COVID-19. Although this study shows promising results, additional studies in larger populations are required to establish a general diagnostic guideline.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Positron Emission Tomography Computed Tomography
/
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Clin Nucl Med
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS